187 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 34.
Movements in equity Retained losses and other reserves amounted to 76 million at 31 December 2018 2017 4,430 million loss: 2016 3,172 million loss of which 337 million 2017 334 million: 2016 329 million relates to joint ventures and associated undertakings.
The cumulative translation exchange in equity is as follows: Net translation exchange included in: NonTotal Retained Fair value controlling translation earnings reserve interests exchange m m m m At 1 January 2016 761 10 109 860 Exchange movements on overseas net assets 633 13 603 1,249 At 31 December 2016 128 23 494 389 Exchange movements on overseas net assets 462 149 313 Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 109 At 31 December 2017 443 23 345 811 Exchange movements on overseas net assets 458 22 1 481 At 31 December 2018 15 1 344 330 The analysis of other comprehensive income by equity category is as follows: NonRetained Other controlling earnings reserves interests Total 2018 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 458 22 480 Fair value movements on cash flow hedges 140 140 Reclassification of cash flow hedges on income and expense 175 175 Deferred tax on fair value movements on cash flow hedges 22 22 Deferred tax reversed on reclassification of cash flow hedges 20 20 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 1 1 Fair value movements on equity investments 180 180 Deferred tax on fair value movements on equity investments 10 10 Remeasurement gains on defined benefit plans 728 728 Tax on remeasurement gains in defined benefit plans 146 146 Other comprehensive income expense for the year 124 131 1 254 NonRetained Other controlling earnings reserves interests Total 2017 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 462 462 Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 109 Fair value movements on available-for-sale investments 14 14 Reclassification of fair value movements on available-for-sale investments 42 42 Deferred tax on fair value movements on available-for-sale investments 47 47 Deferred tax reversed on reclassification of available-for-sale investments 18 18 Fair value movements on cash flow hedges 10 10 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 149 149 Remeasurement gains on defined benefit plans 549 549 Tax on remeasurement gains in defined benefit plans 221 221 Other comprehensive income expense for the year 899 37 149 713 188 GSK Annual Report 2018 Notes to the financial statements continued 34.
Movements in equity continued NonRetained Other controlling earnings reserves interests Total 2016 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 633 13 646 Fair value movements on available-for-sale investments 251 251 Reclassification of fair value movements on available-for-sale investments 245 245 Deferred tax reversed on reclassification of available-for-sale investments 51 51 Reclassification of cash flow hedges to income statement 1 1 Fair value movements on cash flow hedges 2 2 Deferred tax on fair value movements on cash flow hedges 2 2 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 603 603 Remeasurement losses on defined benefit plans 475 475 Tax on remeasurement losses in defined benefit plans 126 126 Other comprehensive income for the year 284 75 603 962 The analysis of other reserves is as follows: ESOP Trust Fair value Cash flow Other shares reserve hedge reserve reserves Total m m m m m At 1 January 2016 75 295 9 2,129 2,340 Exchange adjustments 16 16 Transferred to income and expense in the year on disposals 268 268 Transferred to income and expense in the year on impairments 23 23 Net fair value movement in the year 330 6 336 Ordinary shares acquired by ESOP Trusts 576 576 Write-down of shares held by ESOP Trusts 381 381 At 31 December 2016 286 380 3 2,129 2,220 Exchange adjustments 22 22 Transferred to income and expense in the year on disposals 42 42 Net fair value movement in the year 9 8 17 Ordinary shares acquired by ESOP Trusts 656 656 Write-down of shares held by ESOP Trusts 520 520 At 31 December 2017 400 329 11 2,129 2,047 Implementation of IFRS 9 288 288 At 31 December, as adjusted 400 41 11 2,129 1,759 Exchange adjustments 26 26 Transferred to Retained earnings in the year on disposal of equity investments 94 94 Net fair value movement in the year 193 36 157 Write-down of shares held by ESOP Trusts 265 265 At 31 December 2018 161 140 47 2,129 2,061 Other reserves include various non-distributable merger and pre-merger reserves amounting to 1,849 million at 31 December 2018 2017 1,849 million: 2016 1,849 million.
Other reserves also include the capital redemption reserve created as a result of the share buy-back programme amounting to 280 million at 31 December 2018 2017 280 million: 2016 280 million.
